{
  "generated": "2025-11-05T06:50:25.869105+00:00",
  "policy_fingerprint": "0x6036438e1b958d88",
  "source_evidence": "entries/immune/quercetin-imm-imm11/immune/v1/evidence.csv",
  "preferred_citation": "Kim G. TERVYX Protocol v1.0 (2025).",
  "studies": [
    {
      "study_id": "IMM-IMM11_01",
      "year": 2015,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "antiviral_support",
      "population": "Adults with antiviral support concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/quercetin-imm-imm11-01",
      "url": "https://doi.org/10.1234/quercetin-imm-imm11-01",
      "citation": "IMM-IMM11_01 (2015); Journal: immune_journal; Design: randomized controlled trial; Population: Adults with antiviral support concerns; Outcome: antiviral_support; DOI: 10.1234/quercetin-imm-imm11-01; Adverse Events: None reported."
    },
    {
      "study_id": "IMM-IMM11_02",
      "year": 2016,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "antiviral_support",
      "population": "Adults with antiviral support concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/quercetin-imm-imm11-02",
      "url": "https://doi.org/10.1234/quercetin-imm-imm11-02",
      "citation": "IMM-IMM11_02 (2016); Journal: immune_journal; Design: randomized controlled trial; Population: Adults with antiviral support concerns; Outcome: antiviral_support; DOI: 10.1234/quercetin-imm-imm11-02; Adverse Events: None reported."
    },
    {
      "study_id": "IMM-IMM11_03",
      "year": 2017,
      "design": "randomized controlled trial",
      "journal": "immune_journal",
      "outcome": "antiviral_support",
      "population": "Adults with antiviral support concerns",
      "adverse_events": "None reported",
      "doi": "10.1234/quercetin-imm-imm11-03",
      "url": "https://doi.org/10.1234/quercetin-imm-imm11-03",
      "citation": "IMM-IMM11_03 (2017); Journal: immune_journal; Design: randomized controlled trial; Population: Adults with antiviral support concerns; Outcome: antiviral_support; DOI: 10.1234/quercetin-imm-imm11-03; Adverse Events: None reported."
    }
  ],
  "references": [
    {
      "type": "doi",
      "identifier": "10.1234/quercetin-imm-imm11-01",
      "study_ids": [
        "IMM-IMM11_01"
      ],
      "primary_study_id": "IMM-IMM11_01",
      "url": "https://doi.org/10.1234/quercetin-imm-imm11-01"
    },
    {
      "type": "doi",
      "identifier": "10.1234/quercetin-imm-imm11-02",
      "study_ids": [
        "IMM-IMM11_02"
      ],
      "primary_study_id": "IMM-IMM11_02",
      "url": "https://doi.org/10.1234/quercetin-imm-imm11-02"
    },
    {
      "type": "doi",
      "identifier": "10.1234/quercetin-imm-imm11-03",
      "study_ids": [
        "IMM-IMM11_03"
      ],
      "primary_study_id": "IMM-IMM11_03",
      "url": "https://doi.org/10.1234/quercetin-imm-imm11-03"
    }
  ],
  "manifest_hash": "sha256:9c7a41f2ce208ecfc7845bc8da2035177084a748ca0f517d1e5e2830a1381e6d"
}
